Commentary: HBsAg levels as predictor of sustained response to peginterferon in HBeAg‐negative chronic hepatitis B – author's reply

1. Peng CY, Lai HC, Li YF, et al. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis. Aliment Pharmacol Ther 2012; 35: 458–68. 2. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAgloss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73–82. 3. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAgnegative patients. Hepatology 2009; 49: 1151–7. 4. Hadziyannis E, Vassilopoulos D, Hadziyannis S. Quantitative HBsAg titer as predictor of response to therapy. Curr Hepat Rep 2009; 8: 169–72. 5. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454–61. 6. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg negative chronic hepatitis B. Hepatology 2009; 49: 1141–50. 7. Bonino F, Marcellin P, Lau GKK, et al. Predicting response to peginterferon a-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699–705. 8. Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa2a (40kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008; 2: 102–10. 9. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169–79. 10. Chan HLY, Thomson A, MartinotPeignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report. J Hepatol 2011; 55: 1121–31.